Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC lifted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 37.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,236 shares of the company’s stock after buying an additional 6,000 shares during the period. Trueblood Wealth Management LLC’s holdings in Perspective Therapeutics were worth $71,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Rhumbline Advisers acquired a new stake in Perspective Therapeutics during the 2nd quarter worth about $630,000. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics in the second quarter valued at approximately $117,000. Renaissance Technologies LLC increased its holdings in Perspective Therapeutics by 94.2% in the 2nd quarter. Renaissance Technologies LLC now owns 61,660 shares of the company’s stock worth $615,000 after buying an additional 29,914 shares during the period. HighVista Strategies LLC purchased a new position in Perspective Therapeutics during the 2nd quarter worth approximately $1,132,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Perspective Therapeutics during the 2nd quarter valued at approximately $3,951,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CATX shares. UBS Group assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer lowered their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Truist Financial began coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.14.

Insider Buying and Selling

In other news, CEO Johan M. Spoor purchased 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. This trade represents a 28.31 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jonathan Robert Hunt acquired 12,829 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 67,570 shares of company stock worth $256,789 in the last 90 days. Insiders own 3.52% of the company’s stock.

Perspective Therapeutics Price Performance

Shares of CATX opened at $3.43 on Tuesday. The stock’s 50 day moving average is $4.14 and its two-hundred day moving average is $9.94. Perspective Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, analysts forecast that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.